Global Coalition for Adaptive Research’s Post

Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox

Lastest Case of the Month: Primary or metastatic tumor? – A case report of mucinous adenocarcinoma of pancreas View the case and scans here > https://lnkd.in/es3895Ku

Lastest Case of the Month: Primary or metastatic tumor? – A case report of mucinous adenocarcinoma of pancreas View the case and scans here > https://lnkd.in/es3895Ku

High Tumor Burden: The Kryptonite of CAR T-Cell Therapy? This review focuses on linking the efficacy and safety of CAR T-cell therapy with tumor burden by JAMA

Lastest Case pf the Month: Primary or metastatic tumor? – A case report of mucinous adenocarcinoma of pancreas View the case and scans here > https://lnkd.in/es3895Ku

What if we could open the blood-brain barrier for short periods of time to deliver medication to treat tumor cells? Dr. Sadhana Jackson and her lab are studying which drugs can briefly open the barrier and how this impacts drug delivery and treatment for certain types of brain tumors called gliomas. Listen to learn more: https://go.nih.gov/ln8zGni #NIH_IRP #SpeakingofScience

ctDNA integrated tumor response assessment in immunotherapy can be useful iRECIST or RECIST1.1. A perspective from us https://lnkd.in/dvEpCHxu

Listen to an #audio version of a #pressrelease about "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma." https://lnkd.in/ejXEX-sb

Read about the rationale and design of the ongoing INSIGHT trial, which is investigating ripretinib versus sunitinib for certain patients with advanced gastrointestinal stromal tumor. Discover further details of the paper here:https://hubs.ly/Q02NM5260

The Oncotype DX Recurrence Score® result provides valuable information you can use to help personalize a treatment plan specifically for each patient’s tumor profile. Learn how to help your patients today: #PrecisionOncology #GenomicTesting #OncotypeDX